News Category
Creative Biolabs updates its in vivo CAR-T development portfolio, offering viral and non-viral approaches to streamline direct immune cell engineering...
Lonza's appointment of Samanta Cimitan as its first Chief Commercial Officer underscores its commitment to a unified commercial approach, aiming to en...
The NMPA approval for HDP-101 combination therapy in China marks a pivotal step in expanding treatment options for relapsed/refractory multiple myelom...
A new study published in Critical Care Medicine demonstrates that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality and re...
Monod Bio and SignalChem Biotech announce a non-exclusive licensing agreement to integrate AI-designed LuxSit luciferase and NovoBodies into custom as...
GeoVax Labs secures about $3.6 million through immediate exercise of existing warrants, providing working capital for its clinical programs.
Lakewood-Amedex Biotherapeutics, a clinical-stage biotech developing the novel Bisphosphocin® antimicrobial class, becomes a B2i Digital Featured Comp...
Citius Pharmaceuticals transitions to a commercial-stage biopharma with LYMPHIR's launch, reporting $5.6M in net revenue and advancing late-stage cand...
Annovis Bio announced a corporate update webinar scheduled for September 2, 2026, to discuss progress in its Phase 3 Alzheimer's trial and other key m...
A new, yet-to-be-peer-reviewed study suggests that a personalized mRNA vaccine derived from a patient's tumor tissue can prevent melanoma recurrence y...
Creative Biolabs announces an exclusive webinar on modeling T cell dysfunction in tumor microenvironments, highlighting the importance of understandin...
Synthesis Peptides now provides independent lab Certificates of Analysis for all 40+ compounds, enhancing transparency for researchers.
A novel T cell therapy offers hope for patients with recurrent glioblastoma, a condition with limited treatment options, potentially transforming the ...
VERAXA Biotech and Secarna Pharmaceuticals announced initial positive results from their collaboration on antibody-oligonucleotide conjugates, showing...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate program into preclinical development, marking a key milestone and expanding it...
Scinai Immunotherapeutics reported increased revenue and net income for H1 2026, driven by a bargain purchase gain, while advancing its CDMO business ...
A new scoring system combining biopsy and blood test trends identifies that only a small fraction of early liver rejection cases require treatment, po...
VERAXA Biotech's favorable Scientific Advice from Germany's Paul-Ehrlich-Institute validates its development strategy, reducing uncertainty and clarif...
VERAXA Biotech's proprietary BiTAC platform and recent progress on VXA-222 highlight a novel dual-targeting approach that could improve cancer therapy...
Onco-Innovations has signed a letter of intent to potentially license a novel oral small-molecule LAG-3 inhibitor, which could enhance its immuno-onco...
Creative Biolabs has expanded its complement assay service portfolio, providing researchers with advanced tools to evaluate complement pathway activit...
Quantum BioPharma is advancing Lucid-MS, a myelin-protecting therapy for multiple sclerosis, based on the concept that disability progression can occu...
Silo Pharma's receipt of a Canadian patent allowance for SPC-15 strengthens its global IP position and advances its streamlined regulatory pathway for...
Quantum BioPharma advances its myelin-protecting MS therapy, Lucid-MS, into phase 2 trials, reflecting a broader industry shift toward neuroprotection...
Regentis Biomaterials' recent Japanese patent allowance and U.S. issuance fortify its manufacturing and IP foundation, accelerating GelrinC's path to ...
VERAXA Biotech's collaboration with Ardigen uses artificial intelligence to optimize its BiTAC platform, potentially accelerating drug discovery and r...
VERAXA Biotech's collaboration with Ardigen aims to use AI to identify optimal dual-target combinations for its BiTAC platform, potentially improving ...
Nanox Imaging's subsidiary Nanox AI has entered an exclusive UK reseller agreement with Vertec Scientific to commercialize its FDA-cleared AI bone sol...
Helix BioPharma's appointment of Dr. Markus Loeffler as CMO signals a strategic move to advance its oncology pipeline, particularly L-DOS47 and LEUMUN...
Quantum BioPharma reduced operating expenses significantly and received FDA approval to begin a Phase 2 trial for its lead candidate Lucid-MS, marking...
Regentis Biomaterials is progressing its GelrinC cartilage repair platform with over 50% enrollment in its U.S. Phase III trial and simultaneous Europ...
Helix BioPharma Corp. reshapes its board to align with governance and capital markets needs, appointing CEO Thomas Mehrling as director following Janu...
Onco-Innovations is building the manufacturing and scientific foundation for its nanoparticle-encapsulated PNKP inhibitor ONC010, targeting biomarker-...
Researchers from the University of Manchester discovered that a subset of immune cells, previously understudied, is crucial for initiating and sustain...
Quantum BioPharma reported a significant reduction in operating expenses and FDA approval to proceed with a Phase 2 trial for Lucid-MS, positioning th...
Regentis Biomaterials is simultaneously progressing its cartilage repair product GelrinC through US clinical trials and European commercialization, co...
HeartBeam's Q2 2026 results show significant progress in its heart attack detection program, with cash runway extended into 2027, underscoring its pot...
Lantern Pharma's Q2 2026 results highlight significant pipeline progress and the spin-off of its AI platform, underscoring its strategic shift towards...
NeOnc Technologies' lead candidate NEO100 met its primary endpoint in a Phase 2a trial, showing significant survival benefit in recurrent brain cancer...
Quantum BioPharma's Lucid-MS focuses on preventing disability progression in MS by targeting myelin degradation, a shift from traditional relapse-base...
GeoVax underscores its MVA-based vaccine expertise and candidates as the Bundibugyo Ebola outbreak escalates, positioning itself for potential collabo...
Nutriband's CEO will present at the 2026 Georgia Life Sciences Summit, underscoring the company's commitment to addressing opioid abuse through its AV...
Regentis Biomaterials' new Japanese patent and recent US grant protect its organic solvent-free manufacturing process, boosting scalability and commer...
NeuroThera Labs Inc. closed the first tranche of its non-brokered private placement, raising C$2.7 million to fund working capital and potential strat...
Quantum BioPharma announced FDA approval of its IND application for Lucid-MS, a first-in-class neuroprotective candidate for multiple sclerosis, allow...
PX1 Research's expansion of cGMP quality control and HPLC purity verification to all its US-manufactured research peptides provides academic and resea...
NanoViricides has received regulatory approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a mor...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth and metastasis in TNBC models, supporting ...
